서브메뉴
검색
상세정보
From breakthrough to blockbuster [electronic resource] : the business of biotechnology
![From breakthrough to blockbuster [electronic resource] : the business of biotechnology / D...](/Sponge/Images/bookDefaults/EBbookdefaultsmall.png)
From breakthrough to blockbuster [electronic resource] : the business of biotechnology
상세정보
- 자료유형
- 전자책(국외)
- 미국국회도서관 청구기호
- HD9999.B442-D73 2022
- 자관 청구기호
- 기본표목-개인명
- 표제와 책임표시사항
- From breakthrough to blockbuster [electronic resource] : the business of biotechnology / Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos.
- 출판 정보
- [New York, NY]:Oxford University Press[2022]
- 형태사항
- 1 online resource (1 volume) : illustrations
- 서지 등 주기
- Includes bibliographical references and index.
- 요약 등 주기
- 요약"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--해제Provided by publisher.
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 부출표목-개인명
- 부출표목-개인명
- 기타형태저록
- Print version Drakeman Donald L From breakthrough to blockbuster
- 전자적 위치 및 접속
- 링크정보보기
MARC
008230126s2022 us a sb 001 eng■001on1274229441
■003OCoLC
■00520220519172704.0
■007cr
■010 ▼a2021038557
■019 ▼a1273701378
■020 ▼a9780197626313▼qelectronic book
■020 ▼a0197626319▼qelectronic book
■020 ▼a0197626300▼qelectronic publication
■020 ▼a9780197626306▼q(electronic bk.)
■020 ▼z9780195084009▼qhardcover
■035 ▼a3163596▼b(N$T)
■035 ▼a(OCoLC)1274229441▼z(OCoLC)1273701378
■040 ▼aDLC▼beng▼erda▼cDLC▼dOCLCF▼dOCLCO▼dUKOUP▼dYDX▼dEBLCP▼dOCLCO▼dN$T
■042 ▼apcc
■049 ▼aMAIN
■05004▼aHD9999.B442▼bD73 2022
■08200▼a338.4/76606▼223/eng/20211004
■090 ▼a전자도서
■1001 ▼aDrakeman, Donald L.▼eauthor.
■24510▼aFrom breakthrough to blockbuster▼h[electronic resource] :▼bthe business of biotechnology /▼cDonald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos.
■264 1▼a[New York, NY]▼bOxford University Press▼c[2022]
■300 ▼a1 online resource (1 volume)▼billustrations
■336 ▼atext▼btxt▼2rdacontent
■337 ▼acomputer▼bc▼2rdamedia
■338 ▼aonline resource▼bcr▼2rdacarrier
■504 ▼aIncludes bibliographical references and index.
■520 ▼a"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--▼cProvided by publisher.
■588 ▼aDescription based on publisher webpage ; title from digital cover (viewed on January 31, 2022).
■590 ▼aAdded to collection customer.56279.3
■650 0▼aBiotechnology industries.
■650 6▼aBio-industries.
■650 7▼aBiotechnology industries.▼2fast▼0(OCoLC)fst00832791
■655 4▼aElectronic books.
■7001 ▼aDrakeman, Lisa Natale▼eauthor.
■7001 ▼aOraiopoulos, Nektarios▼eauthor.
■77608▼iPrint version▼aDrakeman, Donald L.▼tFrom breakthrough to blockbuster▼dNew York, NY : Oxford University Press, 2022▼z9780195084009▼w(DLC) 2021038556
■85640▼3EBSCOhost▼uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3163596
■938 ▼aEBSCOhost▼bEBSC▼n3163596
■994 ▼a92▼bN$T
한글
ENG
日本
中文
Việt Nam